|
Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials.
PMID 36064325 · BMC Gastroenterol · 2022-Sep-05
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Clinical Evaluation of an HTK Solution for Liver Transplantation: A Phase 3 Randomized Pilot Clinical Trial Study.
PMID 37543887 · Arch Iran Med · 2022-Sep-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
PMID 35857290 · JAMA Dermatol · 2022-Sep-01
The study is an oncology Phase 3 randomized trial with a drug-containing intervention (topical hypericin) and original results. However, the primary endpoint is a categorical response rate (index lesion response rate), not a time-to-event endpoint. The intervention is a topical photodynamic therapy, which may be considered a device or procedure rather than a systemic drug administration per the criteria. No time-to-event outcomes (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analyses are reported in the abstract.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
PMID 35687757 · Blood · 2022-Sep-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation.
PMID 35583232 · Crit Care Med · 2022-Sep-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever.
PMID 36106542 · Clin Exp Rheumatol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
PMID 36055332 · Lancet Haematol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
PMID 36049817 · JACC Heart Fail · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
PMID 35963261 · Lancet Neurol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
PMID 35961356 · Lancet Glob Health · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
PMID 35934770 · Am J Clin Dermatol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
PMID 35918106 · Clin J Am Soc Nephrol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.
PMID 35917059 · Adv Ther · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
PMID 35914543 · Lancet Diabetes Endocrinol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
PMID 35914542 · Lancet Diabetes Endocrinol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
PMID 35869984 · Ann Hematol · 2022-Sep
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis.
PMID 35817323 · Radiother Oncol · 2022-Sep
主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
|
H
L
B
|
旧查询独有 |
excludedsafety_or_economic_primary_endpoint |
pending
0 Figure · 0 Panel · risk -
|
|
Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.
PMID 35787935 · Eur Urol · 2022-Sep
虽然满足肿瘤学、人类、随机化、III期和原始结果标准,但未检测到明确的time-to-event终点(如OS、PFS等)或Kaplan-Meier/HR证据。此外,虽然标题暗示'Chemoradiotherapy',但未明确检测到药物干预信号,可能为放疗方案而非药物特异性试验。
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
PMID 35785530 · Ann Intern Med · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
PMID 35780807 · Lancet Gastroenterol Hepatol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
PMID 35679950 · Gastroenterology · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.
PMID 35678882 · Support Care Cancer · 2022-Sep
The primary endpoint is the proportion of patients achieving complete hematological response at 12 weeks, which is a binary outcome, not a time-to-event endpoint as defined by the cohort criteria (e.g., OS, PFS, DFS, Kaplan-Meier analysis, HR). Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
PMID 35589610 · Diabetes Obes Metab · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
PMID 35568330 · J Allergy Clin Immunol Pract · 2022-Sep
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
PMID 35546790 · Diabetes Obes Metab · 2022-Sep
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
PMID 35546450 · Diabetes Obes Metab · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
PMID 35537533 · Ophthalmology · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
PMID 35484697 · Br J Dermatol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat.
PMID 35462610 · Clin Exp Nephrol · 2022-Sep
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
PMID 35266417 · Mult Scler · 2022-Sep
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
PMID 35261318 · Mult Scler · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
PMID 35229668 · Mult Scler · 2022-Sep
主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
|
H
L
B
|
旧查询独有 |
excludedsafety_or_economic_primary_endpoint |
pending
0 Figure · 0 Panel · risk -
|
|
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
PMID 34988975 · Br J Dermatol · 2022-Sep
The record is a Phase II RCT assessing feasibility and AK clearance as surrogate biomarkers, not a Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
PMID 34274514 · Clin Gastroenterol Hepatol · 2022-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
PMID 36522208 · Lancet · 2022-Oct-29
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A Preliminary Analysis on the Feasibility and Short-Term Efficacy of a Phase-III RCT on Mindfulness Added to Treatment as Usual for Patients with Chronic Migraine and Medication Overuse Headache.
PMID 36360996 · Int J Environ Res Public Health · 2022-Oct-29
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Mortality after multivessel revascularisation involving the proximal left anterior descending artery.
PMID 35732441 · Heart · 2022-Oct-28
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
VoiceS: voice quality after transoral CO2 laser surgery versus single vocal cord irradiation for unilateral stage 0 and I glottic larynx cancer-a randomized phase III trial.
PMID 36303192 · Trials · 2022-Oct-27
This is a randomized phase III trial in human oncology, but it compares two non-drug interventions (single vocal cord irradiation vs. transoral CO2-laser surgery). The primary endpoint is voice quality (VHI), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Additionally, this is a protocol registration without reported results, making it ineligible.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
PMID 36216650 · Vaccine · 2022-Oct-26
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
PMID 36273481 · Lancet · 2022-Oct-22
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
PMID 36260792 · N Engl J Med · 2022-Oct-20
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
PMID 36150974 · Vaccine · 2022-Oct-19
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Use of mobile data collection systems within large-scale epidemiological field trials: findings and lessons-learned from a vector control trial in Iquitos, Peru.
PMID 36243698 · BMC Public Health · 2022-Oct-15
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
PMID 36226829 · Elife · 2022-Oct-13
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
PMID 35147680 · Clin Infect Dis · 2022-Oct-12
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C.
PMID 36246814 · World J Clin Cases · 2022-Oct-06
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
PMID 35750038 · Jpn J Clin Oncol · 2022-Oct-06
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
PMID 36194218 · JAMA · 2022-Oct-04
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Custodiol-N versus Custodiol: a prospective randomized double-blind multicentre phase III trial in patients undergoing elective coronary bypass surgery.
PMID 35579350 · Eur J Cardiothorac Surg · 2022-Oct-04
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Five-year results of Amaze: a randomized controlled trial of adjunct surgery for atrial fibrillation.
PMID 35348642 · Eur J Cardiothorac Surg · 2022-Oct-04
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|